Researchers at the Emory/Georgia Tech Predictive Health Institute are bolstering the research behind vitamin D and improved heart health and blood pressure.
Researchers at the Emory/Georgia Tech Predictive Health Institute are bolstering the research behind vitamin D and improved heart health and blood pressure.
Emory cardiovascular researcher Ibhar Al Mheid, MD presented findings from a 554-subject trial on vitamin D and heart health at the American College of Cardiology meeting in New Orleans, which began last weekend. Al Mheid found that subjects who increased their vitamin D levels tended to improve vascular health and lower blood pressure.
“There is already a lot known about how vitamin D could be acting here,” said Al Mheid. “It could be strengthening endothelial cells and the muscles surrounding the blood vessels. It could also be reducing the level of angiotensin-a hormone that drives increased blood pressure-or regulating inflammation.”
Al Mheid’s team measured subject vitamin D status via 25-hydroxyvitamin D, a marker of dietary production and skin production of vitamin D. They concluded that 14% of subjects were vitamin D deficient and 33% of subjects were vitamin D insufficient.
Subjects who increased their vitamin D intake over a period of six months, either from dietary supplements or sun exposure, showed a trend towards improved heart health and lowered blood pressure. (Blood pressure was measured by inflating and removing blood pressure cuffs from the arms of subjects and measuring resulting blood flow changes with ultrasound.)
Subjects with unhealthy vitamin D levels were found to have stiffer arteries and poor blood function.
"We found that people with vitamin D deficiency had vascular dysfunction comparable to those with diabetes or hypertension," said Al Mheid.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.